Cells (Aug 2022)

Cellular Therapy Using Epitope-Imprinted Composite Nanoparticles to Remove α-Synuclein from an In Vitro Model

  • Mei-Hwa Lee,
  • Jeng-Shiung Jan,
  • James L. Thomas,
  • Yuan-Pin Shih,
  • Jin-An Li,
  • Chien-Yu Lin,
  • Tooru Ooya,
  • Lilla Barna,
  • Mária Mészáros,
  • András Harazin,
  • Gergő Porkoláb,
  • Szilvia Veszelka,
  • Maria A. Deli,
  • Hung-Yin Lin

DOI
https://doi.org/10.3390/cells11162584
Journal volume & issue
Vol. 11, no. 16
p. 2584

Abstract

Read online

Several degenerative disorders of the central nervous system, including Parkinson’s disease (PD), are related to the pathological aggregation of proteins. Antibodies against toxic disease proteins, such as α-synuclein (SNCA), are therefore being developed as possible therapeutics. In this work, one peptide (YVGSKTKEGVVHGVA) from SNCA was used as the epitope to construct magnetic molecularly imprinted composite nanoparticles (MMIPs). These composite nanoparticles were characterized by dynamic light scattering (DLS), high-performance liquid chromatography (HPLC), isothermal titration calorimetry (ITC), Brunauer–Emmett–Teller (BET) analysis, and superconducting quantum interference device (SQUID) analysis. Finally, the viability of brain endothelial cells that were treated with MMIPs was measured, and the extraction of SNCA from CRISPR/dCas9a-activated HEK293T cells from the in vitro model system was demonstrated for the therapeutic application of MMIPs.

Keywords